CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma

Conclusions: CXCL13 may function as a potential biomarker for predicting prognosis and immunotherapy response and associate with TLSs in HNSCC.PMID:38252495 | PMC:PMC10807398 | DOI:10.1177/03946320241227312

Source: International Journal of Immunopathology and Pharmacology - January 22, 2024 Category: Allergy & Immunology Authors: Xiaohu Lin Xiaomei Zhao Yiming Chen Rong Yang Zhenlin Dai Wei Li Chengzhong Lin Wei Cao Source Type: research